Aura Biosciences, Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Aura Biosciences performed this year. We will break down the company’s progress, their financial health, and what you should watch as an investor.

1. What does this company do?

Aura Biosciences is a biotech company developing "precision" cancer therapies called Virus-like Drug Conjugates (VDCs). They aim to treat solid tumors while keeping the surrounding organ healthy, specifically focusing on eye cancer.

Their lead product, bel-sar, binds to cancer cells. When activated by a laser, it triggers an immune response that destroys the tumor while sparing healthy tissue. As of December 31, 2023, the company is in the pre-commercial stage. They have no sales revenue yet and rely entirely on the success of their clinical trials.

2. Financial health: The "Going Concern" warning

Aura is spending heavily to grow. In 2023, the company lost $107.5 million, compared to a $92.9 million loss in 2022. Most of this spending went toward $82.4 million in research and development.

A critical detail is the "going concern" warning from auditors. Aura had $172.5 million in cash and investments at the end of 2023. This provides enough money to operate into the second half of 2025. The company currently lacks the steady income needed to fund research long-term and relies on selling more stock or finding partners to stay in business. If they cannot raise more money before their cash runs out, they may struggle to finish their clinical trials.

3. Major wins and challenges

The company’s value depends on how well bel-sar performs. In Phase 2 trials for early-stage eye cancer, the drug controlled tumors in 80% of patients. Furthermore, 90% of patients kept their vision. This is a major improvement over current treatments, which often cause permanent vision loss.

Aura is also using its technology to target bladder cancer and has received FDA "Fast Track" status for this program. However, the company faces high risk. Because they rely on one main drug, any safety issues or failed trials would likely cause the stock price to drop significantly.

4. Key risks for investors

• The "All-or-Nothing" Risk: The company’s value is tied to the success of one drug. They have no other products to fall back on if this one fails.
• Dilution: To pay for their $100 million-plus annual costs, Aura frequently sells more shares. This increases the total number of shares, which reduces your ownership percentage.
• Cash Runway: With costs exceeding $8 million per month, the company must keep its stock price high to raise money without hurting shareholders too much.
• Regulatory Hurdles: The FDA may require more expensive trials or stricter monitoring. This could delay the product launch and require more cash.

5. Future outlook

Aura is focused on its Phase 3 trial for eye cancer. Their leadership team has experience from major firms like Eli Lilly and Novartis, which helps when navigating the FDA. They are targeting a massive market in cancer treatment. View Aura as a high-risk, high-reward investment. Success could lead to a buyout or a product launch, but failure to raise money or poor trial results would be a major setback.

---

Investor Takeaway: Before investing, ask yourself if you are comfortable with a company that has no current revenue and a limited cash runway. Aura is a "bet" on the success of a single drug; if you believe in the clinical data for bel-sar, the potential upside is significant, but you must be prepared for the volatility that comes with early-stage biotech companies.